|
|
IFNAR1 |
interferon alpha and beta receptor subunit 1 |
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- Potential therapeutics for SARS
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Evasion by RSV of host interferon responses
|
- Peginterferon alfa-2a
- Interferon alfa-n1
- Interferon alfa-n3
- Peginterferon alfa-2b
- Interferon alfa-2a
- Interferon beta-1a
- Interferon beta-1b
- Interferon alfacon-1
- Interferon alfa-2b
- Interferon alfa
- Human interferon omega-1
- Peginterferon beta-1a
- Anifrolumab
- Human interferon beta
- Ropeginterferon alfa-2b
|
|
|
|
IFNAR2 |
interferon alpha and beta receptor subunit 2 |
|
- Peginterferon alfa-2a
- Interferon alfa-n1
- Interferon alfa-n3
- Peginterferon alfa-2b
- Interferon alfa-2a
- Interferon beta-1a
- Interferon beta-1b
- Interferon alfacon-1
- Interferon alfa-2b
- Human interferon omega-1
- Nylidrin
- Ropeginterferon alfa-2b
|
|
|
|
IGF1R |
insulin like growth factor 1 receptor |
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- IRS-related events triggered by IGF1R
- SHC-related events triggered by IGF1R
- Extra-nuclear estrogen signaling
- Respiratory syncytial virus (RSV) attachment and entry
|
- Insulin human
- Insulin lispro
- Insulin glargine
- Insulin pork
- Mecasermin
- Insulin aspart
- Insulin detemir
- Insulin glulisine
- Phosphoaminophosphonic Acid-Adenylate Ester
- ATL1101
- XL228
- rhIGFBP-3
- Linsitinib
- Teprotumumab
- (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione
- 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE
- Nandrolone decanoate
- Somatrem
- Insulin beef
- Insulin degludec
- Insulin argine
- Insulin peglispro
- Insulin tregopil
- Dalotuzumab
- Cixutumumab
- Brigatinib
- Mecasermin rinfabate
- BMS-754807
- KW-2450 free base
|
- Synovial sarcoma
- Malignant pleural mesothelioma
|
|
|
IL1RAP |
interleukin 1 receptor accessory protein |
|
|
|
|
|
IL23R |
interleukin 23 receptor |
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
|
|
|
|
|
IL2RA |
interleukin 2 receptor subunit alpha |
- RAF/MAP kinase cascade
- RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
- Interleukin-2 signaling
- Interleukin receptor SHC signaling
|
- Denileukin diftitox
- Aldesleukin
- Basiliximab
- Daclizumab
- Inolimomab
- Camidanlumab tesirine
|
- Type I diabetes mellitus
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
|
IL2RB |
interleukin 2 receptor subunit beta |
- RAF/MAP kinase cascade
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Interleukin receptor SHC signaling
|
- Denileukin diftitox
- Aldesleukin
- Basiliximab
- Daclizumab
|
|
|
|
IL6R |
interleukin 6 receptor |
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Interleukin-4 and Interleukin-13 signaling
- Transcriptional regulation of granulopoiesis
- Potential therapeutics for SARS
|
- Tocilizumab
- Sarilumab
- Satralizumab
|
|
|
|
IL6ST |
interleukin 6 cytokine family signal transducer |
- Interleukin-6 signaling
- Interleukin-6 signaling
- IL-6-type cytokine receptor ligand interactions
- Interleukin-35 Signalling
- Interleukin-27 signaling
- Interleukin-27 signaling
|
|
|
|
|
IL7R |
interleukin 7 receptor |
- Interleukin-7 signaling
- Interleukin-7 signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
|
IMPDH2 |
inosine monophosphate dehydrogenase 2 |
- Neutrophil degranulation
- Purine ribonucleoside monophosphate biosynthesis
- Potential therapeutics for SARS
- Azathioprine ADME
|
- NADH
- Mycophenolate mofetil
- Ribavirin
- Mycophenolic acid
- Mercaptopurine
- Selenazole-4-carboxyamide-adenine dinucleotide
- 6-Chloropurine Riboside, 5'-Monophosphate
- Inosinic Acid
- VX-148
|
|
|
|
IRAK1 |
interleukin 1 receptor associated kinase 1 |
- PIP3 activates AKT signaling
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- NOD1/2 Signaling Pathway
- p75NTR recruits signalling complexes
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- TAK1-dependent IKK and NF-kappa-B activation
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Transcriptional Regulation by MECP2
- Interleukin-1 signaling
- IRAK1 recruits IKK complex
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- MyD88 dependent cascade initiated on endosome
- MyD88 cascade initiated on plasma membrane
|
|
|
|
|
JAK1 |
Janus kinase 1 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- ISG15 antiviral mechanism
- Interleukin-7 signaling
- Interleukin-7 signaling
- Other interleukin signaling
- RAF/MAP kinase cascade
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Interferon gamma signaling
- Regulation of IFNG signaling
- Regulation of IFNG signaling
- Interleukin-20 family signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-35 Signalling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Interleukin-21 signaling
- Interferon alpha/beta signaling
- Interleukin receptor SHC signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IFNG signaling activates MAPKs
- Evasion by RSV of host interferon responses
- PD-L1(CD274) glycosylation and translocation to plasma membrane
|
- Myricetin
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Fedratinib
- Filgotinib
- Abrocitinib
- Upadacitinib
- Pralsetinib
- Ivarmacitinib
|
|
|
|
JAK2 |
Janus kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Prolactin receptor signaling
- Prolactin receptor signaling
- Signaling by SCF-KIT
- Signaling by Leptin
- RMTs methylate histone arginines
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF activation
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cyclin D associated events in G1
- Interferon gamma signaling
- Regulation of IFNG signaling
- Regulation of IFNG signaling
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Signaling by Erythropoietin
- Signaling by Erythropoietin
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- IFNG signaling activates MAPKs
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Factors involved in megakaryocyte development and platelet production
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- XL019
- 5-phenyl-1H-indazol-3-amine
- 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
- 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
- Ruxolitinib
- Tofacitinib
- Pacritinib
- Baricitinib
- Entrectinib
- Fostamatinib
- Fedratinib
- Abrocitinib
- Zanubrutinib
- Pralsetinib
|
|
|
|
JAK3 |
Janus kinase 3 |
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by ALK
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-20 family signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-21 signaling
- Interleukin receptor SHC signaling
- Potential therapeutics for SARS
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- R-348
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Zanubrutinib
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
|
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
- Pre-NOTCH Transcription and Translation
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- FCERI mediated MAPK activation
- Activation of the AP-1 family of transcription factors
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- MAPK6/MAPK4 signaling
- TP53 Regulates Transcription of DNA Repair Genes
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Estrogen-dependent gene expression
- WNT5:FZD7-mediated leishmania damping
- Signaling by ALK fusions and activated point mutants
- Regulation of PD-L1(CD274) transcription
|
- Adapalene
- Vinblastine
- Pseudoephedrine
- Irbesartan
- Arsenic trioxide
- LGD-1550
|
|
|
|
KAT5 |
lysine acetyltransferase 5 |
- Formation of the beta-catenin:TCF transactivating complex
- Formation of the beta-catenin:TCF transactivating complex
- DNA Damage/Telomere Stress Induced Senescence
- HATs acetylate histones
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Sensing of DNA Double Strand Breaks
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Estrogen-dependent gene expression
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
- Cardiogenesis
|
- Coenzyme A
- S-Acetyl-Cysteine
|
|
|
|
KDM1A |
lysine demethylase 1A |
- HDACs deacetylate histones
- HDMs demethylate histones
- Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
- Regulation of PTEN gene transcription
- Estrogen-dependent gene expression
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- Potential therapeutics for SARS
- Negative Regulation of CDH1 Gene Transcription
- Factors involved in megakaryocyte development and platelet production
|
|
|
|
|
KHDRBS1 |
KH RNA binding domain containing, signal transduction associated 1 |
- PTK6 Regulates Proteins Involved in RNA Processing
|
|
|
|
|
KLF15 |
KLF transcription factor 15 |
- BMAL1:CLOCK,NPAS2 activates circadian expression
|
|
|